BAY 41-8543
BAY 41-8543 is a pharmacological compound that acts as a soluble guanylate cyclase (sGC) activator. It is primarily used in research settings to study the role of sGC in various physiological and pathological processes.
Mechanism of Action[edit | edit source]
BAY 41-8543 functions by directly stimulating soluble guanylate cyclase, an enzyme that catalyzes the conversion of GTP to cGMP. This process is independent of nitric oxide (NO), which is the natural activator of sGC. By increasing cGMP levels, BAY 41-8543 can induce vasodilation and has potential therapeutic applications in conditions characterized by impaired NO signaling.
Pharmacological Effects[edit | edit source]
The activation of sGC by BAY 41-8543 leads to increased levels of cGMP, which in turn causes relaxation of vascular smooth muscle cells. This results in vasodilation and a subsequent decrease in blood pressure. The compound has been studied for its potential benefits in treating pulmonary hypertension, heart failure, and other cardiovascular diseases.
Research and Development[edit | edit source]
BAY 41-8543 has been extensively studied in preclinical models to understand its effects on the cardiovascular system. It has shown promise in improving hemodynamics and reducing symptoms in animal models of heart failure and pulmonary hypertension. However, its clinical development has been limited, and it is not currently approved for therapeutic use in humans.
Potential Applications[edit | edit source]
Due to its ability to activate sGC independently of NO, BAY 41-8543 is of interest in conditions where NO signaling is impaired, such as in certain types of endothelial dysfunction. It may also have applications in neurodegenerative diseases and other conditions where cGMP signaling plays a crucial role.
Safety and Side Effects[edit | edit source]
As with many pharmacological agents, the safety profile of BAY 41-8543 is an important consideration. In preclinical studies, it has been generally well-tolerated, but potential side effects could include hypotension due to excessive vasodilation.
Also see[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
